Aeterna Zentaris Appoints Geneviève Lemaire as Vice President, Finance and Chief Accounting Officer
February 18 2016 - 3:24PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”)
today announced the appointment of Ms. Geneviève Lemaire, currently
Interim Corporate Controller, to serve as the Company’s Vice
President, Finance and Chief Accounting Officer. Ms. Lemaire is a
chartered professional accountant in Canada and Certified Public
Accountant, registered in the State of Illinois. She has worked in
various accounting and audit functions for Ernst & Young in
Canada and Switzerland and in senior finance and accounting
functions in other organizations. Ms. Lemaire will be the principal
financial officer overseeing the completion and filing of the
Company’s 2015 annual audited consolidated financial statements and
the related documents and filings, while also providing the overall
leadership in the finance and accounting function within the
Company.
The Company also announces that Mr. Keith Santorelli, the
Company’s former Vice President, Finance and Chief Accounting
Officer, has left the Company to pursue other opportunities. Mr.
Santorelli served as the Company’s principal financial officer
after the Company’s reorganization of its finance and accounting
function was implemented in early October 2015.
Mr. David A. Dodd, Chairman, President and Chief Executive
Officer of the Company, commented on the developments, stating, “I
would like to thank Keith for serving the Company well during its
period of transition. I am looking forward to working with
Geneviève more closely as she helps us transition our finance and
accounting operation to our Charleston office. Geneviève has a
great deal of knowledge of the Company as she has been serving, on
a contract basis, as our Interim Corporate Controller since last
August. She will continue to serve on a contract basis in her new
position while we staff our finance and accounting function in
Charleston on a permanent basis.”
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We are now conducting Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition or license of products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
territories where such out-licensing would enable us to ensure
development, registration and launch of our product candidates. Our
goal is to become a growth-oriented specialty biopharmaceutical
company by pursuing successful development and commercialization of
our product portfolio, achieving successful commercial presence and
growth, while consistently delivering value to our shareholders,
employees and the medical providers and patients who will benefit
from our products. For more information, visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the US Securities
Litigation Reform Act of 1995. Forward-looking statements may
include, but are not limited to statements preceded by, followed
by, or that include the words “expects,” “believes,” “intends,”
“anticipates,” and similar terms that relate to future events,
performance, or our results. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects and clinical trials, the successful and timely
completion of clinical studies, the risk that safety and efficacy
data from any of our Phase 3 trials may not coincide with the data
analyses from previously reported Phase 1 and/or Phase 2 clinical
trials, the ability of the Company to efficiently commercialize one
or more of its products or product candidates, the ability of the
Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory
process, the ability to protect our intellectual property, the
potential of liability arising from shareholder lawsuits and
general changes in economic conditions. Investors should consult
the Company's quarterly and annual filings with the Canadian and US
securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking
statements. The Company does not undertake to update these
forward-looking statements. We disclaim any obligation to update
any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained herein
to reflect future results, events or developments, unless required
to do so by a governmental authority or by applicable law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160218006659/en/
Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice
Presidentir@aezsinc.com
American Oil & Gas Common Stock (NYSE:AEZ)
Historical Stock Chart
From May 2024 to Jun 2024
American Oil & Gas Common Stock (NYSE:AEZ)
Historical Stock Chart
From Jun 2023 to Jun 2024